56 filings
Page 3 of 3
8-K
d2c2d
18 Nov 21
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat
4:58pm
8-K
xegcxmjdumdg cgo
12 Nov 21
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results
8:00am
8-K
ssk7jm1fq8 qz6
1 Oct 21
Regulation FD Disclosure
4:02pm
8-K
zi0a3 zt917o9
29 Sep 21
Regulation FD Disclosure
9:31am
8-K
mpcouxnxrw4zz f2a
9 Sep 21
Regulation FD Disclosure
9:28am
8-K
rfwkzbgn234v
13 Aug 21
Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty
1:46pm
8-K
udwivzq 9nb6oy
13 Aug 21
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results
10:32am
8-K
khyf80
23 Jul 21
Departure of Directors or Certain Officers
4:01pm
8-K
4xgjiry m8mdx9r1t
25 May 21
Longeveron Announces the Appointment of Ursula Ungaro to its Board of Directors
10:15am
8-K
hl63y6mds2itza0 0ss6
14 May 21
Results of Operations and Financial Condition
8:54am
8-K
gza5h7boi
11 May 21
Regulation FD Disclosure
11:42am
8-K
28hdn
15 Apr 21
Regulation FD Disclosure
9:08am
8-K
0u1nu
13 Apr 21
Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease
9:18am
8-K
hrukvx194uex i8f
30 Mar 21
Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
9:03am
8-K
thjug5 bd1gtnl3uq
15 Mar 21
Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
4:30pm
8-K
k2wlb9jvspo7n8zygd
9 Mar 21
Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations
4:21pm